Clinical Trial Protocol Information

Clinical trial protocol information for active or completed studies are available below.

If you are a patient, physician, or researcher seeking more information about Takeda’s active or completed clinical trials in the Japanese language please click here.


All Clinical Trial Protocol Information

Search

C26003

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)
www.clinicaltrials.gov/ct2/show/NCT02202785

MLN3126_103

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Ascending Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 i...
www.clinicaltrials.gov/ct2/show/NCT02209506

TAK-536/CCT-001

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension
clinicaltrials.gov/ct2/show/NCT01289132

SYR-322_02

An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes
clinicaltrials.gov/ct2/show/NCT01289119

TAK-390MR_206

A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent S...
clinicaltrials.gov/ct2/show/study/NCT01642602

TAK-875_306

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects With Type 2 Diabetes and Wi...
clinicaltrials.gov/ct2/show/study/NCT01609582

AG-1749 (CCT-351)

A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.
clinicaltrials.gov/ct2/show/NCT00762359

TAK-475 (TL-011)

A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 (100 mg) Vs Placebo When Coadministered With Atorvastatin (10 or 20 mg) in Subjects With Primary Hypercholesterolemia
clinicaltrials.gov/ct2/show/NCT00864643